Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T ...

In LAVA-1207’s absence, Lava will now be bumping up LAVA-1266, which is due to enter the clinic before the end of the year.

IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company focused on developing therapies using engineered gamma-delta T cells, finds itself at a critical juncture in its development.

The latest update is out from Century Therapeutics ( (IPSC) ).

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA ...

Hiranmoy Das, Ph.D., a professor of pharmaceutical sciences at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy, has been named a Fellow of the National ...

IN8bio (INAB) announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in ...

AlloCell has been used in ten prior cell therapy clinical trials and with the addition of the ACHIEVE trial is being actively used in four clinical trials. The ACHIEVE clinical trial is an adaptive, ...

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA ...